AbbVie and Iambic have entered a multi-year collaboration to accelerate the discovery of small molecule drugs using Iambic's AI-driven platform. This partnership aims to improve the efficiency and success rate of identifying new drug candidates in immunology, neuroscience, and oncology. Iambic's advanced AI technology, including its Enchant v3 model, will help test multiple drug design hypotheses simultaneously, reducing timelines and increasing precision. The collaboration supports AbbVie's commitment to innovation and delivering breakthrough medicines to patients faster.
AbbVie shares trade at USD 262.53 on Pluang as of Sep 21, 2026 19:02 WIB, showing a slight 0.47% decrease in one day. The company holds a substantial market cap of $466.45 billion and offers a dividend yield of 2.62%. This collaboration announcement aligns with AbbVie's ongoing innovation efforts in the health sector, where it maintains a strong market presence.
AbbVie presented new data from real-world studies showing VRAYLAR (cariprazine) significantly improves depressive symptoms, functioning, and quality of life in adults with major depressive disorder (MDD) and bipolar I (BP-I) depression. These studies...
AbbVie announced that its investigational drug etentamig met the dual primary endpoints of objective response rate and progression-free survival in a Phase 3 study for relapsed/refractory multiple myeloma. The results were presented at the 23rd Inter...
